On January 11, 2024, Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on NASDAQ under the trading symbols ADIL and ADILW for its common stock and warrants respectively, held a Special Meeting of Stockholders. During this meeting, stockholders voted on two key proposals. The first proposal, known as the Warrant Exercise Proposal, sought approval for the issuance of up to 3,007,092 shares of common stock upon the exercise of warrants related to a private placement offering that concluded on October 24, 2023. This issuance could potentially exceed 20% of the company's outstanding common stock prior to the offering. The proposal received approval with 432,915 votes in favor, 51,550 against, and 6,621 abstentions. The second proposal, the Adjournment Proposal, was to approve the adjournment of the Special Meeting to...Show More

On January 11, 2024, Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on NASDAQ under the trading symbols ADIL and ADILW for its common stock and warrants respectively, held a Special Meeting of Stockholders. During this meeting, stockholders voted on two key proposals. The first proposal, known as the Warrant Exercise Proposal, sought approval for the issuance of up to 3,007,092 shares of common stock upon the exercise of warrants related to a private placement offering that concluded on October 24, 2023. This issuance could potentially exceed 20% of the company's outstanding common stock prior to the offering. The proposal received approval with 432,915 votes in favor, 51,550 against, and 6,621 abstentions. The second proposal, the Adjournment Proposal, was to approve the adjournment of the Special Meeting to a later date if necessary. However, this was not required as the Warrant Exercise Proposal passed without the need for further solicitation of votes. The Adjournment Proposal also passed with 436,338 votes in favor, 47,809 against, and 6,939 abstentions. The results of the meeting were filed with the SEC and are detailed in the company's definitive proxy statement.